Form 10-Q Unicycive Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Noble Capital Reiterates Outperform Rating on Unicycive Therapeutics (UNCY)
May 14, 2024 8:44 AM EDTNoble Capital analyst Robert LeBoyer reiterated an Outperform rating and $6.00 price target on Unicycive Therapeutics (NASDAQ: UNCY).
The analyst comments "We Believe OLC Will Have Advantages Over Other Phosphate Binding Drugs.
OLC was formulated to reduce pill burden and improve compliance in... More
